Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221789 | 1.00 | TACR1 (0.56) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL2855186 | 0.88 | PPARA (0.61) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL2855187 | 0.88 | PPARA (0.61) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL2852419 | 0.86 | ALDH1A1 (0.65) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL2852421 | 0.86 | ALDH1A1 (0.65) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL7307413 | 0.86 | PPARA (0.67) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL2969722 | 0.86 | PPARA (0.67) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL9825847 | 0.86 | PPARA (0.67) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL5399121 | 0.84 | GPR34 (0.71) | PPARAITGB3ITGA2B | |
| SCHEMBL2857463 | 0.84 | CTSL (0.57) | TACR1CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624311-B2 | Forming roxifiban | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | BRITOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | ANPEP, DAO, DNPEP | TACR1 2596/4885CTSK 1112/4885CTSL 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.